Your browser is no longer supported. Please, upgrade your browser.
Settings
VRX [NYSE]
Valeant Pharmaceuticals International, Inc.
Index- P/E74.10 EPS (ttm)2.67 Insider Own2.30% Shs Outstand334.26M Perf Week-3.14%
Market Cap66.13B Forward P/E16.03 EPS next Y12.35 Insider Trans5.09% Shs Float324.93M Perf Month-1.69%
Income913.50M PEG2.97 EPS next Q2.31 Inst Own66.80% Short Float1.97% Perf Quarter40.98%
Sales8.26B P/S8.00 EPS this Y198.90% Inst Trans21.20% Short Ratio2.04 Perf Half Y54.80%
Book/sh15.81 P/B12.51 EPS next Y17.83% ROA3.30% Target Price52.38 Perf Year55.55%
Cash/sh0.97 P/C204.99 EPS next 5Y24.95% ROE17.60% 52W Range106.00 - 206.84 Perf YTD38.24%
Dividend- P/FCF36.25 EPS past 5Y19.20% ROI8.40% 52W High-4.35% Beta0.91
Dividend %- Quick Ratio1.20 Sales past 5Y58.70% Gross Margin72.70% 52W Low86.64% ATR5.96
Employees16800 Current Ratio1.50 Sales Q/Q10.50% Oper. Margin34.80% RSI (14)54.62 Volatility2.59% 2.87%
OptionableYes Debt/Eq2.87 EPS Q/Q321.60% Profit Margin11.10% Rel Volume0.32 Prev Close198.46
ShortableYes LT Debt/Eq2.87 EarningsMay 07 Payout0.00% Avg Volume3.14M Price197.84
Recom3.00 SMA20-1.43% SMA509.60% SMA20040.46% Volume1,016,887 Change-0.31%
Feb-25-15Reiterated CRT Capital Buy $180 → $220
Feb-24-15Reiterated UBS Buy $165 → $222
Feb-24-15Reiterated Stifel Buy $175 → $230
Feb-12-15Reiterated RBC Capital Mkts Outperform $188 → $191
Feb-09-15Initiated Barclays Overweight $200
Jan-09-15Reiterated UBS Buy $155 → $165
Feb-28-14Reiterated UBS Buy $141 → $170
Feb-28-14Reiterated RBC Capital Mkts Outperform $151 → $158
Feb-27-14Reiterated Aegis Capital Buy $160 → $180
Jan-08-14Reiterated UBS Buy $125 → $141
Jan-08-14Reiterated Ladenburg Thalmann Buy $123 → $155
Jan-08-14Reiterated FBR Capital Outperform $130 → $153
Dec-03-13Reiterated UBS Buy $115 → $125
Nov-01-13Reiterated Ladenburg Thalmann Buy $127 → $123
Oct-30-13Initiated FBR Capital Outperform $130
Oct-07-13Reiterated CRT Capital Buy $110 → $130
Aug-08-13Reiterated UBS Buy $96 → $115
Aug-07-13Reiterated Aegis Capital Buy $135 → $140
Jul-02-13Reiterated RBC Capital Mkts Outperform $76 → $100
Jun-10-13Upgrade CRT Capital Hold → Buy $100
Mar-28-15 07:00AM  Hyperion Could Be Next Pharma Target With Orphan Drugs: Real M&A at Bloomberg
Mar-27-15 11:35PM  13D Filings at Barrons.com
04:10PM  VALEANT PHARMACEUTICALS INTERNATIONAL, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial
04:06PM  Is Antitrust a Risk in the Life Time Fitness Merger?
12:06PM  Life Time Fitness: An Activity for Everyone
11:06AM  Point72 Reduces Its Stake in Valeant Pharmaceuticals
10:19AM  Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares at noodls
10:09AM  Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares PR Newswire
10:09AM  Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares CNW Group
Mar-26-15 06:06PM  Transaction Basics of the Life Time Fitness Merger
01:36PM  FactSet: U.S. M&A Activity Dips in February as Private Equity Surges at Barrons.com
12:53PM  Kraft Foods And The Rise Of Wall Street's Buy And Hold Kingpins at Forbes
11:18AM  Actavis takes 'specialty pharma' route to health at Financial Times
09:35AM  With New Valeant Pharmaceuticals Intl Inc (VRX) Stake, Bill Ackman Maintains Large Exposure to Healthcare Sector at Insider Monkey
Mar-25-15 03:28PM  Ackman Boosts Stake In Valeant; Still Appears To Be Passive
01:45PM  On Zero-Based Budgeting, Activists at Knee of 3G at The Wall Street Journal
08:50AM  Valeant Pharmaceuticals (VRX): An Off-the-Radar Potential Winner - Tale of the Tape
Mar-24-15 02:35PM  Salix had a $13B offer on the table before accounting problems crashed share price at bizjournals.com
11:57AM  Edelman, iShares Launch Exponential Technologies ETF ETF Trends
11:57AM  Edeleman, iShares Launch Exponential Technologies ETF ETF Trends
10:50AM  Talking Allergan at Tulane: a 'Horse Choker,' the 'Shamarendum' and More at The Wall Street Journal
08:48AM  Can Valeant Pharmaceuticals (VRX) Keep the Earnings Streak Alive This Quarter? - Tale of the Tape
Mar-23-15 11:05AM  The Federal Reserve: Patient No More?
11:05AM  Eminence Capital Downs Position in Valeant Pharmaceuticals
08:49AM  Surging Earnings Estimates Signal Good News for Valeant Pharmaceuticals (VRX) - Tale of the Tape
07:00AM  Actavis' Wide-Moat Transformation Offers Shareholder Rewards at Morningstar
01:36AM  Point72 Asset Managements New Position in Gilead Sciences
Mar-22-15 09:44AM  DURECT Corporation (DRRX): First Eagle Raises Its Stake; See Investors Other Healthcare Picks at Insider Monkey
Mar-21-15 08:02AM  Drug Stocks Are Hot: Meet The 5 Best On The IBD 50 at Investor's Business Daily
12:39AM  Last Week at Barrons.com
12:01AM  Review at Barrons.com
Mar-20-15 05:05PM  Why the Feds Patience Has Ironically Created Quite a Stir
02:41PM  Week in Review, March 21 at Financial Times
10:05AM  Valeant Pharmaceuticals Issuance Dominates Leveraged Loans
08:55AM  Why Valeant Pharmaceuticals (VRX) Could Be an Impressive Growth Stock - Tale of the Tape
Mar-19-15 06:06PM  Baupost Group Slightly Reduced Its Stake in Syneron Medical
04:06PM  High Yield Bond Inflows Turn Negative for the First Time in 7 Weeks
01:35PM  Salix execs including two that resigned to receive $78M in golden parachutes at bizjournals.com
12:05PM  Pharmaceuticals and Industrials Dominate High Yield Bond Issuance Market Realist
Mar-18-15 06:05PM  High Yield Debt Issuance Hits its Highest Point in 2015 So Far
05:10PM  Valeant (VRX) Prices Shares to Finance Salix Acquisition - Analyst Blog
12:47PM  Salix's New Deal Yields More Fees for J.P. Morgan, Centerview at The Wall Street Journal
12:27PM  Salix Executives Who Left After Financial Errors Get $46 Million at Bloomberg
12:27PM  How Salix's Executives Got Paid Millions Even After Quitting
09:42AM  Investors in health-care stocks get rich as M&A booms at MarketWatch
09:30AM  The Zacks Analyst Blog Highlights: Valeant Pharmaceuticals International, Salix Pharmaceuticals, Endo International and Allergan - Press Releases
08:02AM  This Drugmaker Stock Is Attempting A Re-Breakout at Investor's Business Daily
06:04AM  VALEANT PHARMACEUTICALS INTERNATIONAL, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Mar-17-15 10:45PM  Obama crackdown fails to stop foreign mergers at CNNMoney.com
09:49PM  Sale of Allergan to Actavis is finalized; CEO David Pyott stepping down at Los Angeles Times
06:25PM  Actavis, Impax Labs Extend Winning Ways at Investor's Business Daily
05:44PM  Valeant (VRX) Raises Salix Offer, Endo Withdraws Proposal - Analyst Blog
12:09PM  Valeant Bonds Trade Higher, Despite Skepticism at Barrons.com
10:46AM  Valeant Bumps Its Offer to $173 to Seal the Salix Deal
09:16AM  Valeant Pharmaceuticals Prices Offering Of $1.45 Billion Of Common Shares at noodls
09:00AM  Valeant Pharmaceuticals Prices Offering Of $1.45 Billion Of Common Shares PR Newswire
09:00AM  Valeant Pharmaceuticals Prices Offering Of $1.45 Billion Of Common Shares CNW Group
08:05AM  Bidding Wars and Smart Beta
05:55AM  For health-care stocks, buy what executives are buying at MarketWatch
12:16AM  Overheard: Valeants High-Cost M&A Treatment at The Wall Street Journal
Mar-16-15 11:12PM  Valeant Wins Battle for Salix Pharmaceuticals at The Wall Street Journal
07:41PM  Valeant Wins Salix After Raising Offer at The Wall Street Journal
06:29PM  Valeant Wins Salix With Hiked $173-A-Share Bid
05:33PM  Valeant's High-Cost M&A Treatment -- Overheard at The Wall Street Journal
05:05PM  The Salix-Endo Proposal: Basics of the Transaction
05:00PM  Stocks End Higher Ahead of Fed Meeting
04:44PM  Valeant increases Salix bid; Endo pulls out of bidding at Los Angeles Times
04:39PM  Valeant Pharmaceuticals Announces Offering Of $1.45 Billion Of Common Shares at noodls
04:32PM  CANADA STOCKS-TSX climbs on upbeat sentiment ahead of Fed meeting
04:08PM  VALEANT PHARMACEUTICALS INTERNATIONAL, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Eve
04:01PM  Valeant Pharmaceuticals Announces Offering Of $1.45 Billion Of Common Shares PR Newswire
04:01PM  Valeant Pharmaceuticals Announces Offering Of $1.45 Billion Of Common Shares CNW Group
03:07PM  Why Valeant Had to Increase Salix Bidand Endo Had to Walk Away at Barrons.com
03:05PM  Stocks Extend Session Highs as Wall Street Gears Up For Fed Meeting at TheStreet
03:00PM  Dealpolitik: Valeant Sprints to Avoid a Marathon for Salix at The Wall Street Journal
02:29PM  Raised offer from Valeant knocks Endo out of Salix race at Financial Times
01:56PM  Valeant Pharma (VRX) Increases Bid for Salix (SLXP) to $173/share - Stocks in the News
01:41PM  Unfazed by Accounting Woes, Salix Bidders Drive Up Deal Price at Bloomberg
01:40PM  Stocks Hold Near Day's Highs; Medical Issues Gain at Investor's Business Daily
01:27PM  Robert Durst Arrested on Murder Charge, and More at MarketWatch
01:16PM  Skadden Wins, and Also Loses, as Valeant Nabs Salix in Bidding War at The Wall Street Journal
01:06PM  Valeant/Salix: resistance is futile at Financial Times
01:05PM  What Investors Need to Know about Endo International
01:04PM  Watchman device approval boosts Boston Scientific at Financial Times
01:01PM  Valeant Boosts Offer for Salix to $15.8 Billion, Endo Drops Bid at TheStreet
12:56PM  Valeant trumps Endo with $11 billion bid for Salix Pharma Reuters
12:44PM  Valeant trumps Endo with $10.96 billion bid for Salix Pharma Reuters
12:42PM  The Hottest Question in Pharma: Which Company Will Be Next To Sell? at The Wall Street Journal
12:11PM  Valeant wins Salix with sweetened $11B deal at USA TODAY
12:00PM  Valeant ups Salix bid to $11.11B and Endo ends quest
12:00PM  Stocks Higher Ahead of Fed Meeting
11:03AM  Netflix downgraded; Edwards rallies on positive study results at MarketWatch
11:00AM  Valeant Pharmaceuticals Poised To Win Bidding War For Salix With $173 A Share Cash Deal at Forbes
10:58AM  European Commission Clears Actavis Deal to Buy Allergan at The Wall Street Journal
10:50AM  Valeant Beats Endo to Salix in Sweetened $11.1B Offer at Bloomberg
10:43AM  Endo Drops Salix Bid On Raised Valeant Offer at Investor's Business Daily
10:36AM  Stocks Post Solid Gains At Open; Valeant Gets Salix, Endo Cedes at Investor's Business Daily
10:30AM  Bidding war for Salix shows confidence in its lead drug at bizjournals.com
10:24AM  Canada Stocks Rise as Valeant Climbs to Record on Deal at Bloomberg
10:19AM  Valeant boosts bid for Salix; Endo drops out at bizjournals.com
Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. The company offers Solodyn to treat red and pus-filled pimples of acne in patients, as well as Ziana, Acanya, Atralin, Retin- A Micro, and ONEXTON gel; Wellbutrin XL for major depressive disorder in adults; Jublia for onychomycosis of the toenails; Xenazine for chorea; Targretin for Cutaneous T-Cell Lymphoma; Arestin, a subgingival sustained-release antibiotic; and PROVENGE for the treatment of prostate cancer. It also provides Zovirax, an antiviral for recurrent herpes labialis and initial genital herpes; Syprine to treat patients with Wilson's disease; Elidel to treat atopic dermatitis; Prolensa for inflammation and pain following cataract surgery; Duromine, a weight loss drug; and Lotemax gel for post-operative inflammation and pain. In addition, the company offers PreserVision, an antioxidant eye vitamin and mineral supplement; CeraVe to rebuild and repair the skin barrier; ReNu Multiplus to lubricate and rewet soft contact lenses; Biotrue for healthy contact lens wear; Ocuvite, a lutein eye vitamin and mineral supplement; Boston, a cleansing solution for gas permeable contact lenses; Artelac to treat dry eyes; AntiGrippin for acute respiratory and respiratory viral diseases, and influenza; and Bedoyecta, a vitamin B complex product. Further, it provides SofLens daily disposable contact lenses; PureVision, a contact lens; various ophthalmic surgical products; Biotrue ONEday lens; medical device systems for aesthetic applications; and Bausch + Lomb Ultra, a contact lens. Additionally, the company offers Tobramycin and Dexamethasone ophthalmic suspension for steroid responsive inflammatory ocular conditions; Cardizem CD to treat hypertension and angina; and Latanoprost for the treatment of glaucoma. Valeant Pharmaceuticals International, Inc. was founded in 1983 and is headquartered in Laval, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Chai-Onn Robert RoswellEVP, CLO, General CounselMar 03Option Exercise6.1021,808133,02943,187Mar 04 05:24 PM
Chai-Onn Robert RoswellEVP, CLO, General CounselMar 02Option Exercise25.4290,9392,311,669112,296Mar 04 05:24 PM
Chai-Onn Robert RoswellEVP, CLO, General CounselMar 02Sale200.0190,93918,189,09121,379Mar 04 05:24 PM
Mirovsky PavelEVP, Pres. & GM Valeant EMEAFeb 27Option Exercise0.0010,000010,000Mar 02 05:16 PM
Stolz Brian M.EVP, Administration and CHCOJan 22Option Exercise0.007,350095,934Jan 26 05:22 PM
Schiller Howard BradleyEVP, Chief Financial OfficerJan 05Option Exercise0.0045,0000318,714Jan 07 05:38 PM
Stolz Brian M.EVP, CHCO and AdministrationDec 23Option Exercise0.0015,426096,618Dec 24 10:31 AM
Farmer Ronald HaroldDirectorDec 12Buy160.4850080,24033,004Dec 16 02:59 PM
UBBEN JEFFREY WDirectorDec 10Buy139.2950,0006,964,50018,030,936Dec 11 06:59 PM
UBBEN JEFFREY WDirectorDec 09Buy140.25200,00028,050,00017,980,936Dec 11 06:59 PM
STEVENSON KATHARINE BERGHUISDirectorDec 03Buy145.731,500218,59523,098Dec 03 04:48 PM
Farmer Ronald HaroldDirectorNov 24Buy163.951,000163,95032,504Dec 01 05:25 PM
UBBEN JEFFREY WDirectorNov 24Buy142.25210,00029,872,50017,780,936Nov 26 04:11 PM
Stolz Brian M.EVP, Administration and CHCOOct 10Option Exercise0.003,675084,791Oct 14 02:51 PM
Schiller Howard BradleyEVP and CFOOct 03Option Exercise0.0022,5000285,500Oct 07 04:19 PM
Stolz Brian M.EVP, Administration and CHCOSep 30Option Exercise0.0023,030093,064Oct 02 03:52 PM
Stolz Brian M.EVP, CHCO and AdministrationAug 06Option Exercise0.0018,111079,431Aug 07 03:53 PM
Chai-Onn Robert RoswellEVP, Gen. Couns. & Corp. Secy.Jun 23Option Exercise6.4510,20365,80934,202Jun 24 04:37 PM
Chai-Onn Robert RoswellEVP, Gen. Couns. & Corp. Secy.Jun 23Sale121.7010,2031,241,67623,999Jun 24 04:37 PM
Mirovsky PavelPresident of Valeant EuropeJun 02Sale131.2510,0001,312,4860Jun 04 03:19 PM
Chai-Onn Robert RoswellEVP, Gen. Couns. & Corp. Secy.May 13Option Exercise6.4510,00064,50033,999May 14 04:29 PM
Chai-Onn Robert RoswellEVP, Gen. Couns. & Corp. Secy.May 13Sale130.0810,0001,300,83623,999May 14 04:29 PM
Provencio Norma AnnDirectorApr 01Sale132.185,000660,886137,495Apr 02 04:55 PM